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Abstract
The objective of this trial was to assess the long-term effect of the CHANGE lifestyle coach-
ing intervention for 428 people with abdominal obesity and schizophrenia spectrum disor-
ders on cardiovascular risk. In this randomized, superiority, multi-center clinical trial,
participants were randomized to 12 months of either lifestyle coaching plus care coordina-
tion (N = 138), care coordination alone, (N = 142) or treatment as usual (N = 148). There
was no effect after 12 months, but we hypothesized that there might have been a delayed
treatment effect. Our primary outcome at two-year follow-up was 10-year risk of cardiovas-
cular disease standardized to 60 years of age.
After two-years the mean 10-year cardiovascular-disease risk was 8.7% (95% confi-
dence interval (CI) 7.6–9.9%) in the CHANGE group, 7.7% (95% CI 6.5–8.9%) in the care
coordination group, and 8.9% (95% CI 6.9–9.2%) in the treatment as usual group (P = 0.24).
Also, there were no intervention effects for any secondary or exploratory outcomes, includ-
ing cardiorespiratory fitness, weight, physical activity, diet and smoking. No reported
adverse events could be ascribed to the intervention. We conclude that there was neither
any direct nor any long-term effect of individual lifestyle coaching or care coordination on
cardiovascular risk factors in people with abdominal obesity and schizophrenia spectrum
disorders. The trial was approved by the Ethics Committee of Capitol Region Copenhagen,
Denmark (registration number: H-4-2012-051) and the Danish Data Protection Agency (reg-
istration number: 01689 RHP-2012-007). The trial was funded by the Mental Health
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Introduction
Life expectancy in people with severe mental illness is reduced with up to 30 years compared to
the background population[1], [2]. Age specific mortality rates for cardiovascular disease and
other physical illnesses are 2 to 3 fold higher than in the general population with cardiovascular
disease being the most common cause of death[1]. The increased morbidity and mortality can
be explained by several risk factors, with factors related to lifestyle choices contributing largely
[3]. Disparities in health care add to the excess mortality[4] as patients with severe mental ill-
ness are less likely to be tested for even the simplest of metabolic risk factors, such as blood glu-
cose, dyslipidemia, and blood pressure[1]. Somatic health problems are therefore widely
underdiagnosed and undertreated among people with severe mental illness[1].
Systematic reviews of randomised clinical trials assessing the effect of behavioral interven-
tions for reduction of cardiovascular risk factors in people with severe mental illness, have
shown small to moderate effects[5]. The current evidence is based on trials with short follow
up—no longer than six months post intervention[6] and we lack knowledge about the long-
term effects.
The objective of the CHANGE trial was to investigate the effect of an intensive lifestyle
intervention that aimed to create sustainable enhancement of the cumulative health profile of
people with schizophrenia spectrum disorders. The CHANGE trial used a comprehensive
approach and addressed not only obesity, as the correlation between weight loss and mortality
remains questionable[7]. Thus, we aimed at reducing several cardiovascular risk factors by
• Facilitating smoking cessation.
• Enhancing physical activity.
• Improving healthy dietary habits.
• Ensuring monitoring and treatment of already occurring health problems like hypertension,
diabetes, and dyslipidemia.
The hypothesis was that a 12-months individually tailored lifestyle coaching intervention
would reduce the estimated 10-year cardiovascular-disease risk of, and that the effects would
be sustainable with positive results remaining at two-years follow-up. The trial design and the
one-year results are described elsewhere[8], [9], and showed no effect of the intervention com-
pared with treatment as usual on any outcomes. Based on our theoretical framework Motiva-
tional Interviewing and Stages of Change, participants might theoretically have moved from
lower towards higher levels of motivation to change health behaviour, resulting in post-
intervention weight loss, smoking cessation, improved cardiorespiratory fitness etc. The cur-
rent report describes the two-years follow-up results in order to detect a possible late onset
effect of the examined interventions.
Methods
Study design and participants
This study describes the two-years follow-up results of the CHANGE trial, which was a multi-
center randomised clinical trial conducted in Denmark’s two largest cities (Copenhagen and
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Aarhus) during the period December 2012 through May 2014. The trial was investigator-initi-
ated and independently funded. The trial protocol was published in 2015[8], see supporting
informatin S1 File, and one-year post intervention results were published in 2016[9].
The participants were 18+ years old, and diagnosed according to the ICD-10 with schizo-
phrenia (F20), schizoaffective disorder (F25), or persistent delusional disorder (F22)–con-
firmed at initial assessment by the Schedules for Clinical Assessment in Neuropsychiatry
(SCAN)[10]–and with a waist circumference above the cut-off points for substantial risk of
metabolic complications suggested by the WHO[11] (102 cm for men and 88 cm for women).
Patients were excluded if they were currently pregnant or unable to give written informed
consent.
The Copenhagen Trial Unit performed computerised central randomization with variable
block sizes (9, 12, and 15) in a 1:1:1 ratio to one of three groups: lifestyle coaching, care coordi-
nation, and treatment as usual (CHANGE intervention); care coordination and treatment as
usual; or treatment as usual alone. Randomisation was stratified according to sex, site, and risk
of cardiovascular disease at baseline. The latter was split into high/low using cutoff points
of15% risk of cardiovascular event for men and 7% for women in the next 10 [12], using the
Copenhagen risk score[13] with age standardized to 60 years.
According to our protocol[8], all data published as main results of the study were blinded
for statisticians and researchers. However, as the blinding was broken just prior to publication
of the main results, the analyses performed in the present follow-up were not blinded.
Interventions
CHANGE intervention. The CHANGE intervention consisted of one year of affiliation
with a CHANGE coach, who was a healthcare professional (physiotherapists, occupational ther-
apists, or dieticians) with clinical experience in psychiatry and with special training in smoking
cessation, healthy dieting, and monitoring and treatment of lifestyle diseases. Lifestyle coaching
was based on the transtheoretical model (stages of change)[14], motivational interviewing[15],
and used an assertive approach[16]. The latter involved the coach offering at least one personal
meeting per week or home visit of variable duration, often one hour, besides phone calls, test
messages, and e-mails. The coaches aimed to motivate and support the participants in finding
realistic and attractive options for daily-life physical activity, healthy dietary choices (involving
purchasing of food and cooking sessions), and—where relevant—smoking cessation.
Each coach was assigned a maximum of 15 participants. All contacts with participants were
registered by the lifestyle coaches. Besides the abovementioned intervention, the CHANGE
intervention included care coordination and continued treatment as usual as described below.
After 12 months of the CHANGE intervention all participants received treatment as usual.
Care coordination. Care coordination consisted of one year of being affiliated to a care
coordinator who was a special trained psychiatric nurse, facilitating contact for the participants
to the primary care sector in order to secure optimal treatment of physical health problems.
Symptoms of cardiovascular disease, diabetes, or obstructive pulmonary disease were main
focuses.
The care coordinator offered personal meetings, assistance at visits to the participants gen-
eral practitioner, home visits, phone calls, and text-message contact with participant, and
adjusted the frequency according to the individual need.
The care coordinator to participant ratio was 1:40 and as for the CHANGE intervention all
contacts with participants were registered by the care coordinator. The care coordination
included continued treatment as usual as described below. After 12 months of the care coordi-
nation intervention all participants received treatment as usual.
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Treatment as usual. The participants randomised to treatment as usual received no extra
lifestyle counselling or treatment of physical disorders besides what is offered from the public
health care system. All people in Denmark have affiliation to a general practitioner with free
consultation when needed. People with severe mental illness are treated in secondary mental
health service, and people treated with antipsychotics receive at least yearly mandatory screen-
ing of metabolic risk factors. All patients retained contact with their usual general practitioner,
who monitors and treats somatic diseases. All results from baseline and the two follow-up
assessments were available to the participant or their usual carer, and the CHANGE research
team contacted the participant or their usual carer if any result was of serious concern.
The interventions are described in greater detail and manuals are provided in the previous
published trial protocol[8].
Outcome assessments
Outcome assessments were done just after end of the interventions (described elsewhere[9])
and at two-years follow-up. The primary outcome was the estimated 10-year cardiovascular-
disease risk, standardised to age 60 years using the Precard[13] score, a composite measure
developed for two epidemiological studies inCopenhagen[12]. Precard consists of non-
modifiable (sex, family history of cardiovascular disease, diabetes mellitus and prior heart dis-
ease) and modifiable factors (daily smoking (yes/no), total and high density lipoprotein (HDL)
cholesterol, body mass index, and systolic blood pressure). The algorithm estimated the abso-
lute risk of ischemic heart disease, myocardial infarction, stroke, or death within the next 10
years. We standardised this risk by estimating it as though all participants were 60 years of age,
according to the recommendations by the European Guidelines on Cardiovascular Disease
Prevention in Clinical Practice[17].
Our secondary outcomes were cardiorespiratory fitness (VO2max test performed on a bicy-
cle), weight, body mass index, lung capacity (Easy-one1 spirometer), systolic blood pressure
(average of three measurements from the right upper arm, with the participant sitting upright
after resting for 10 minutes, and prior to the bicycle test), waist circumference, resting heart
rate, HDL and total cholesterol, hemoglobin A1c, and self-reported level of moderate and vig-
orous physical activity (Physical Activity Scale[18]).
We also investigated the following exploratory outcomes: high sensitivity C-reactive pro-
tein, triglycerides, self-reported sedentary time, daily smoking (Fagerstro¨m Test for Nicotine
Dependence)[19], diet (using a 24-hours recall interview and Food Frequency Questionaire
[20]), symptoms of schizophrenia (cale for the Assessment of Positive Symptoms (SAPS)[21]
and the Scale for the Assessment of Negative Symptoms (SANS)[22]), cognition (Brief Assess-
ment of Cognition in Schizophrenia[23]), quality of life (Manchester Short Assessment of
Quality of Life[24]), psychosocial functioning (Global Assessment of Functioning[25]), and
perceived health[26].
Statistical analysis
Power calculations are described in detail in the previous post intervention publication[9].
The original enrolment target was 450 participants, which provided 90% power to detect a dif-
ference between groups on risk of a cardiovascular event 2.5 percentage-points at 12 months.
Analyses were by the intention-to-treat principle. Linear mixed-model analysis with
repeated measures and unstructured covariance matrix was used to calculate the estimated
outcomes for all continuous measures. Analyses were adjusted for sex, center, and baseline car-
diovascular-disease risk. Histograms were assessed for normal distribution, and any skewness
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was handled by the fact that the mixed-model analysis is robust for violation of the normality
assumption.
For the one dichotomous outcome smoking status we used multiple imputation with the
predictors: sex, age, randomisation, smoking status at baseline and at one year follow-up. 100
imputations and 20 iterations were conducted. Analyses were then performed using binary
logistic regression on the imputed datasets, adjusting for sex, research center, and Precard.
Sensitivity analyses included complete-case analyses, outlier-removal (three standard devia-
tions above or below estimated mean), and excluding participants without any contacts (per-
protocol analysis).
We calculated post hoc the proportion of participants who gained or lost respectively 5 or
10 percent of their bodyweight during the two years using chi-square tests.
All statistical analyses were conducted using SPSS v. 22.
Deviations from the protocol
Due to lack of referrals we only included 428 participants, i.e. 22 fewer than planned.
Results
We included 428 participants from two sites (279 in Copenhagen and 149 in Aarhus). These
were randomised to CHANGE intervention (N = 138), care coordination (N = 142), or treat-
ment as usual (N = 148). The dataset is available, see supporting information S2 File, and the
flow of patients through the trial can be seen in Fig 1. The mean age was 38.6 years (Range 18
to 68 years, Standard deviation (SD) 12.4), 240 (56%) were female. The majority had a diagno-
sis of schizophrenia (88%); while the remainder had either schizoaffective disorder (11%) or
psychotic disorder not otherwise specified (1%). Most were prescribed antipsychotic medica-
tion (n = 408, 95%), 127 (30%) were on either olanzapine or clozapine, the two antipsychotic
drugs with the highest risk of causing weight gain, diabetes and cardiovascular risk[27] and
166 (39%) received more than one antipsychotic agent. The mean duration of illness was 17.5
years (SD 1.9) with a range from 10 months to 64 years. The mean duration of untreated psy-
chosis was 4.5 years (SD 6.7), with a range from 0 days to 36 years. The proportion of partici-
pants lost to follow-up was 21% at 2-years for the sample as a whole. There were no differences
in the dropout proportions in the three groups (P = 0.39). Table 1 shows baseline metabolic,
psychometric and medication characteristics for the dropouts and completers, respectively.
The only difference between dropouts and completers was a slightly higher score in the
completers for the cognitive test BACS.
Table 2 presents an overview of results on our primary and secondary outcome measures.
There were no indications of statistically significant effects of any intervention compared to
the other two on any outcome measure. We found that our primary outcome, mean age-stan-
dardised 10-year cardiovascular-disease risk was 8.7% (SD 6.0%) in the CHANGE group, 7.7%
(SD 5.7%) in the care coordination group, and 8.0% (SD 6.3%) in the treatment as usual group
(P = 0.24). In sensitivity analyses of complete cases, the 10-year risks were 9.0% (SD 5.9%) in
the CHANGE group, 8.1% (SD 6.0%) in the care coordination group, and 7.8% (SD 6.1%) in
the treatment as usual group (P = 0.08). Removal of six outliers or of three participants with no
contacts had no statistically significant impact on the results.
Table 3 shows the percentages of participants meeting certain weight thresholds at two
years after randomization, using chi-square tests.
The proportion of participants who at two years had lost at least 5% of their baseline weight
was 25.4% in the CHANGE group, 19.7% in the care coordination group, and 16.9% in treat-
ment as usual group (P = 0.20).
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There were no statistically significant differences between groups for any of the other sec-
ondary or exploratory outcomes including cardiorespiratory fitness, BMI, blood lipids and
hbA1c, smoking status and lung function, psychotic symptoms, subjective wellbeing, level of
functioning and quality of life (Table 2).
ANOVA comparing mean weight and waist in participants receiving and not-receiving
antipsychotic medication, respectively, did not show any significant difference, neither at base-
line nor at two years follow-up. Also Pearsons corellations showed no association between
antipsychotic medication dosage (as Daily Defined Doses) and weight or waist circumference,
respectively, neither at baseline nor at two years follow-up.
Fig 1. Flow diagram showing the process of recruiting and follow up through the CHANGE trial.
https://doi.org/10.1371/journal.pone.0185881.g001
PLOS ONE | https://doi.org/10.1371/journal.pone.0185881 October 6, 2017 6 / 13
Adverse events
As seen in Table 3, the proportions of participants who gained 5% and 10% of their baseline
weight, respectively in the three intervention groups were not statistically different. Thirteen
participants died during the two-year follow-up period; two in the CHANGE group, seven in
the care coordination group, and four in the treatment as usual group, respectively (P = 0.20).
No deaths or other adverse events were reported that could be ascribed to the intervention.
Discussion
Principal findings
The aim of this randomized clinical trial was to investigate the long-term effects of a multi-
domain personal coaching intervention, addressing the risk of cardiovascular disease in partic-
ipants with schizophrenia spectrum disorders plus overweight in a community setting. The
findings from 2-years follow-up of the intervention showed that neither the CHANGE inter-
vention plus care coordination, nor care coordination groups achieved superior outcomes
when compared with the treatment as usual group in reducing the cardiovascular-disease risk.
No significant differences were found between the two intervention groups and the control
group, neither in composite cardiovascular disease risk score, cardiovascular fitness, dietary
habits, physical activity, psychiatric symptoms, cognition, perceived health or quality of life.
These findings are in line with the previously reported results from the first one-year follow-
up directly post-intervention, which also showed no significant difference between the three
intervention groups in any outcome[9].
Table 1. Comparing baseline values for participants missing/not missing at two-years follow-up using ANOVA.
Not missing Missing P
SD SD
Sex (%Female) 56 56 51 0.370
Age (years, mean±SD) 39.04 12.36 36.99 12.47 0.157
Schizophrenia (%) 88 89 0.722
Employment yes/no (%) 3 3 0.929
Duration of Illness (years, mean±SD) 17.62 10.92 16.91 10.87 0.589
Supported housing (%) 09 15 0.093
Antipsychotics yes/no (%) 96.11 92.55 0.150
Polypharmacia yes/no (%) 39.82 35.11 0.409
Smoking yes/no (%) 50.60 57.45 0.241
Weight (kg, mean±SD) 102.86 21.26 103.30 23.84 0.863
BMI (kg/m2, mean±SD) 34.15 5.79 34.20 6.52 0.948
Waist circumference (cm, mean±SD) 114.55 14.60 114.74 15.61 0.911
Systolic blood pressure (mmHg, mean±SD) 127.78 126.85 0.577
Total cholesterol (mmol/l, mean±SD) 5.01 1.09 5.08 1.14 0.598
HDL (mmol/l, mean±SD) 1.22 0.37 1.24 0.42 0.659
Psychotic symptoms (SAPS, mean±SD) 2.12 1.61 2.45 1.55 0.074
Negative symptoms (SANS, mean±SD) 2.50 1.14 2.73 1.29 0.102
Cognition (BACS, mean±SD) 228.31 48.68 213.00 49.59 0.010
Level of functioning (GAF, mean ±SD) 44.03 44.03 42.63 7.93 0.121
SAPS—Scale for the Assessment of Positive Symptoms, SANS—Scale for the Assessment of Negative Symptoms, BACS—Brief Assessment of Cognition
in Schizophrenia, GAF—Global Assessment of Functioning, HDL#x2014;high density lipoprotein
https://doi.org/10.1371/journal.pone.0185881.t001
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Table 2. Results for primary and secondary outcomes at 2 years using linear mixed-models.
Change Care
coordinator
Treatment
as usual
P
(group x time)
Primary outcome
10-year risk of cardiovascular disease (%)
Mean±SDa 8.7±6.0 7.7±5.7 8.0±6.3 0.235
Secondary outcomes
Weight (Kg)
Mean±SDa 105.9±22.2 103.7±22.1 104.9±22.1 0.177
Body mass index
Mean±SDa 35.6±8.6 34.4±8.7 34.4±8.6 0.131
Waist circumference (cm)
Mean±SDa 114.8±17.0 114.9±17.1 117.0±16.8 0.834
Systolic blood pressure (mm Hg)
Mean±SDa 129.1±13.0 130.1±13.5 128.3±13.4 0.522
Resting heart rate (beats/min)
Mean±SDa 82.3±13.7 85.1±13.8 85.5±13.7 0.534
Cardiorespiratory fitness (ml O2/min/Kg)
Mean±SDa 17.7±5.8 19.0±5.8 17.5±5.8 0.717
Forced expiratory volume (L/min)
Mean±SDa 3.1±0.6 3.2±0.6 3.1±0.6 0.614
HbA1c (mmol/mol)
Mean±SDa 39.7±7.8 39.3±8.1 39.3±8.0 0.731
Total cholesterol (mmol/l)
Mean±SDa 5.02±1.0 4.94±1.0 5.04±1.1 0.693
HDL cholesterol (mmol/l)
Mean±SDa 1.12±0.3 1.2±0.4 1.28±0.3 0.447
Triglycerides (mmol/l)
Mean±SDa 2.1±1.7 2.1±1.8 2.3±1.8 0.665
Hs-CRP (mg/l)
Mean±SDa 5.3±5.3 5.0±5.4 4.7±5.4 0.446
Moderate-vigorous physical activity (hours/week)
Mean±SDa 2.6±5.9 2.9±5.9 2.8±6.0 0.811
Time spent Sedentary (hours/day)
Mean±SDa 10.4±3.7 10.3±3.7 10.3±3.6 0.839
Daily smoking (yes/no)
% (chi-square statistics)b 50.7 (0.03) 47.6 (0.01) 49.3 (0.01) 0.963
Intake of fruit (g/week)
Mean±SDa 346.6±201.0 331.1±229.1 334.6±216. 0.392
Intake of vegetables (g/week)
Mean±SDa 542.1±294.8 455.6±295.1 486.6±294.7 0.061
Intake of fish (g/week)
Mean±SDa 119.0±113.9 137.0±114.0 139.7±113.7 0.746
Positive symptoms (SAPS global score)
Mean±SDa 1.6±1.1 1.5±1.3 1.4±1.2 0.174
Negative symptoms (SANS global score)
Mean±SDa 1.7±1.0 1.5±1.0 1.5±1.1 0.781
Cognition (BACS composite score)
Mean±SDa 254.3±44.9 251.2±45.6 251.6±46.5 0.445
(Continued )
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The lack of hypothesised intervention effect makes it irrelevant to talk of sustenance. How-
ever, one might have hypothesised a delayed treatment effect, which would be visible after a
year post-intervention. This was, however, not the case, indicating that our motivational
approach did not enhance motivation in the participants to change lifestyle choices, neither in
the short- nor in the longer term.
Strengths and limitations
CHANGE is to our knowledge the largest lifestyle intervention trial in people with schizophre-
nia spectrum disorder and overweight. External validity was high as we had very few exclusion
criteria, an assertive recruitment process, and provision of an intervention without mandatory
components. This methodological strength implies a challenge obtaining positive results, as
recent research suggests that intrinsic motivation is important when it comes to adopting and
maintaining of health promoting behaviours[28]. Using a less pragmatic design and including
only trial participants who expressed readiness to change health behaviours may likely have
led to more positive results, which, however, would only be applicable to the motivated parts
of the population.
The trial used central randomisation, blinding of outcome assessors, data managers, and
data analysts, and funding agencies had no impact on analyses or conclusions[8]. Our recruit-
ment and retention rates were sufficient to not let power issues affect our conclusions. The
intervention was manual-based and based on a solid foundation of evidence and theory[14],
[15]. We compared lifestyle coaching with care coordination, which allowed us to tease out
potential differential effects of lifestyle changes and those of improving monitoring and
Table 2. (Continued)
Change Care
coordinator
Treatment
as usual
P
(group x time)
Quality of life (MANSA score)
Mean±SDa 4.8±0.1 4.9±0.1 4.9±0.1 0.60
GAF total score
Mean±SDa 48.6±10.8 48.1±10.7 48.1±10.78 0.792
Perceived health
Mean±SDa 3.4±0.9 3.4±0.9 3.4±0.9 0.849
Hs-CRP—high sensitivity C-reactive protein, SAPS—Scale for the Assessment of Positive Symptoms, SANS—Scale for the Assessment of Negative
Symptoms, BACS—Brief Assessment of Cognition in Schizophrenia, MANSA—Manchester Short Assessment of Quality of Life, GAF—Global Assessment
of Functioning, HDL—high density lipoprotein HbA1c—hemoglobin A1c
a after mixed model analysis, adjusted for sex, research center and baseline risk of cardiovascular disease
b after imputation with predictors: sex, age, randomization, smoking status at baseline and 1 year follow-up. 100 imputations, 20 iterations
https://doi.org/10.1371/journal.pone.0185881.t002
Table 3. Percentages of participants meeting certain weight thresholds at two years after randomization using chi square tests.
Change Care coordinator Treatment as usual P-value
% of participants
Min 5% weight loss 25.36 19.72 16.89 0.200
Min 10% weight loss 11.59 11.27 8.78 0.697
Min 5% weight gain 20.29 20.42 21.62 0.954
Min 10% weight gain 12.32 6.34 8.78 0.219
https://doi.org/10.1371/journal.pone.0185881.t003
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treatment of somatic illnesses and conditions. The intervention was sustainable, with a focus
on identifying low-budget possibilities in the participants’ local environments.
Limitations include the fact that our primary outcome Precard has not been validated in a
population with severe mental illness, and the generalisability of cardiovascular risk scores
from the general population to people with severe mental illness has been questioned[29].
Another potential limitation regarding the Precard as outcome is that it included non-
modifiable risk factors and therefore required a stronger effect on the modifiable factors in
order to affect the composite measure. However, there was no indication of significant reduc-
tions in any of the separate modifiable risk factors, which makes this issue less relevant.
Another limitation to our trial is that we did not assess the participants’ level of motivation
or stage of change at any time point, wherefore we do not have knowledge of possible enhance-
ment of readiness to change, that might predict possible future positive results either by con-
tinuation of the CHANGE intervention or exploitation of this hypothesised increased
readiness to change by a different kind of intervention.
Strengths and weaknesses in relation to other studies
The results for our secondary outcomes; cardiorespiratory fitness and weight reduction are
not in line with previous trials[5], which is probably attributable to different patient character-
istics and types of interventions. Even though most previous evidence is reported to be favour-
able, the external validity is sparse and long-term trials are missing.
Another limitation consists of self-reporting of physical activity and eating behaviour.
Potential recall bias may have led to random type II errors, and social desirability bias may
have caused systematic errors. Direct measurements such as actigraphs may have been more
accurate, but were not logistically and economically possible in our study. As for the measur-
ing of dietary intake no method seems to be able to estimate habits and accurate intake without
error. Assessing dietary habits under controlled or laboratory-like conditions is likely to influ-
ence dietary habits in the short-term, thus under-estimating regular eating patterns[30]. We
believe that our chosen assessment methods were the best possible.
Regarding our theoretical framework for the intervention, the transtheoretical model and
Motivational Interviewing are widely used in health promotion programmes for smoking ces-
sation, healthy dieting, and physical activity[31], though documentation for the effect on last-
ing lifestyle change is sparse. Reviews of trials using the models in the general population
found very low quality evidence for improvements in dietary and physical activity habits[32]
or smoking cessation[33].
Explanations and implications for clinicians and policymakers
Since only 42.8% of participants in the CHANGE group attended at least 50% of the planned
sessions, it does not appear likely that increasing the number of sessions or decreasing the
caseload would have yielded more positive results. Mean attendance was 24.6 sessions (SD
14.5, range 0–70). Making mandatory elements such as training groups, free healthy meals, or
incentivising attendance or goals such as weight loss or smoking cessation with monetary or
other kinds of reward may have led to positive results[34], but such interventions would be
more expensive and doubtfully sustainable and thus would not easily be implemented in a
real-world-setting.
An important notion is that even in the non-psychiatric background population, health
behaviour changes are not easily achieved and maintained[35]. Behavioral interventions tar-
geting both physical activity, diet and smoking cessation show modest yet significant benefits
but evidence is generally sparse on long-term effects[36]. The landmark study Look Ahead
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found that intensive lifestyle intervention among patients with diabetes was successful in pro-
moting weight loss and improving most cardiovascular risk factors as long as the intervention
went on, but did not decrease cardiovascular events over an approximately 10-year follow-up
period[37].
The control condition, treatment as usual, may partly explain the non-superiority of the
care coordinator intervention as well as the CHANGE intervention, as health care is free and
easily accessible in Denmark. Analyses of lipids or blood pressure at baseline did not indicate
that participants in the CHANGE trial should change their medication. Furthermore, we only
found two cases with no prior known history of diabetes in which HbA1c values indicated the
presence of diabetes. Consequently, it cannot be excluded that an additional effect of care coor-
dination over treatment as usual this trial could be present in countries with different health
care systems. Also, merely being enrolled in the project, even in the control group, may have
increased the awareness in participants on cardiovascular risk and the importance of healthy
lifestyle choices (the so called Hawthorne effect), thus affecting their behaviour in a positive
way causing a “spill over” effect with a hypothetical impact on the study outcome.
Our motivational approach based on the belief that it is possible to achieve behavioral
changes even in unmotivated people may not be the right one to improve life for participants
with schizophrenia. Suggestions for future research could be structural approaches—such as
giving free healthy meals in institutions or small monetary rewards for healthy behavior such
as loss of weight (within the limits of feasibility). Furthermore, multimodality-approaches
could be considered, for example combining pharmacological treatment[38] (metformin,
GLP-analogues, etc.) with behavioral intervention, or making use of internet- or telephone-
based technologies. Several apps are available that target cardiovascular risk-factors for
instance by exercise prescription or integration of patient information exchange with general
practitioners, but the research field is still too young to provide evidence based solutions[39].
In conclusion, there were no indications of delayed or long-term benefits of the CHANGE
life-style coaching intervention or care coordination over treatment as usual, in patients with
abdominal obesity and schizophrenia spectrum disorders.
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